Actavis plc’s (NYSE:ACT) new drug application (NDA) for its antibiotic candidate, ceftazidime-avibactam, has been accepted for review by the FDA. Actavis is looking to get ceftazidime-avibactam approved for the treatment of patients with complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI), including those caused by multi-drug resistant gram-negative bacterial pathogens. Actavis plc (NYSE:ACT) belongs to Healthcare sector. Its net profit margin is 0.60% … Continue reading Morning Alert : Actavis (NYSE:ACT), Borderfree (NASDAQ:BRDR), Sohu.com (NASDAQ:SOHU), Rowan Companies (NYSE:RDC), Platform Specialty Products (NYSE:PAH)